A First Biologic for Axial Spondyloarthritis, Eighteen Months Before She Wants to Conceive
Guidelines call TNF and IL-17 inhibitors equally reasonable first biologics for her disease. The actual disagreement is about whether that equivalence survives contact with an eighteen-month conception plan, and whether it's the drug class or one specific drug within it that the plan should be built around.
Danielle R. has spent eighteen months telling herself the ache across her low back and buttocks was just what four years of climbing utility poles and kneeling inside transformer vaults does to a body — until a rheumatology referral, prompted by six weeks of morning stiffness that no longer loosened by lunch, found sacroiliitis on MRI and an HLA-B27 result that reframed the whole history. Her CRP came back at 18 mg/L, more than three times the upper limit of normal and high enough that "worked hard yesterday" stops being a plausible explanation on its own. Two NSAID trials at maximal dose, six weeks apart, brought her BASDAI down from 7.4 to only 6.2 — still active disease by any working definition, which is what actually opens the door to a first biologic rather than a third analgesic trial.
She is not vague about what she wants next: she and her husband are planning to start trying to conceive in roughly a year to eighteen months, and she wants that plan built into today's choice rather than revisited later as an emergency substitution. The 2026 ACR/SAA/SPARTAN update states plainly that TNF and IL-17 inhibitors are equally recommended as an initial biologic for active axSpA, with no efficacy edge for either class on the joints and spine she actually has to live in. That equivalence is real, and it is also the wrong altitude for her actual question. Antibody structure, not drug class, governs how much of a given biologic an active placental transporter carries across the placenta as pregnancy advances — a property that varies within the TNF class itself, not just between TNF and IL-17 inhibition, and that a class-level guideline recommendation was never built to adjudicate.
Her pre-biologic screening — hepatitis B and C serologies, an interferon-gamma release assay for latent tuberculosis, a baseline complete blood count and comprehensive metabolic panel — came back reassuring across every measure, leaving no barrier to starting today beyond the choice of which drug to start with. On exam she has reduced lateral lumbar flexion and a positive bilateral FABER test, findings consistent with an eight-week-old imaging study rather than a rapidly evolving one. The twelve-to-eighteen months is the softest number in the case, and the one the whole discussion is being built on: a conception timeline is a plan, not a measurement, and it can collapse to three months or stretch past three years without anyone doing anything wrong.
Choosing a first biologic, eighteen months out
Start certolizumab pegol. The CRIB study measured cord blood at delivery across all three trimesters and found essentially no active transport of certolizumab across the placenta — not a favorable ratio, an undetectable one, because the molecule lacks the Fc region that placental transporters recognize. The 2020 ACR reproductive health guideline names it specifically as a preferred agent in patients planning pregnancy. She has eighteen months to find out this drug controls her disease before it also has to do the harder job of controlling it through a pregnancy.
You're right that CRIB is the strongest single dataset we have on any biologic in this space — but let's be precise about what it actually supports. It's a finding about one molecule's structure, not a verdict on TNF inhibition versus IL-17 inhibition as classes. The 2026 guideline's equipoise between the two classes for her actual joint disease is real evidence, and quietly narrowing "start a biologic" to "start a TNFi" because of a certolizumab-specific result overstates what that one study settles.
Several IL-17 inhibitors now carry multi-year prospective pregnancy-registry follow-up without a distinct signal of harm, which is a different kind of evidence than CRIB's direct pharmacokinetic measurement, but it isn't nothing — it shouldn't be treated as disqualifying next to a single trial's precision.
Both of you are arguing the pregnancy question a year early. The decision that's actually live today is which drug she gets established on, at a dose proven to work, without a preconception switch disrupting that stability right when she wants predictability most. A flare during an induction period for a newly started drug is a worse outcome than most single-agent exposure profiles we're debating. Certolizumab lets her start now and simply continue — no planned washout, no drug change timed around ovulation. That continuity is the actual reproductive-health argument here, not just the CRIB number by itself.
Agreed: certolizumab pegol 200 mg subcutaneously at weeks 0, 2, and 4, then every two weeks; naproxen continued as needed; BASDAI and CRP rechecked at 12 weeks to confirm real response before she and her husband move ahead with their own timeline.
Not fully agreed, and left explicit rather than smoothed over: whether the class-level equipoise between TNF and IL-17 inhibitors should be revisited if certolizumab doesn't control her disease at 12 weeks. The rheumatologist would cycle to a second TNFi with a similarly favorable structural profile before reaching for a class switch; the clinical pharmacologist sees no principled reason to prefer that over moving straight to an IL-17 inhibitor if certolizumab genuinely fails, since nothing about today's reproductive-planning argument would still apply to a drug that isn't working.